VIKING THERAPEUTICS, INC. (VKTX) Total liabilities 2016–2025
VIKING THERAPEUTICS, INC. (VKTX) total liabilities at each fiscal year-end, per SEC filings.
$76.7MFY2025 · since FY2016: $6.5M → $76.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $76.7M | +173.4% |
| FY2024 | $28.0M | +39.7% |
| FY2023 | $20.1M | -13.5% |
| FY2022 | $23.2M | +164.4% |
| FY2021 | $8.8M | -27.8% |
| FY2020 | $12.2M | +70.4% |
| FY2019 | $7.1M | +56.4% |
| FY2018 | $4.6M | -47.3% |
| FY2017 | $8.7M | +33.3% |
| FY2016 | $6.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More VKTX financial trends
VKTX RevenueVKTX Net incomeVKTX Net marginVKTX Gross profitVKTX Gross marginVKTX Operating incomeVKTX Operating marginVKTX Operating cash flowVKTX Free cash flowVKTX Capital expendituresVKTX Return on equityVKTX Stock buybacksVKTX Dividends paidVKTX Total assetsVKTX Shareholders’ equityVKTX overview →